

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 to 2 (Cancelled)

Claim 3 (Previously Presented) A compound of claim 18 wherein:

$R^2$  is  $(C_1-C_4)$ alkyl substituted with  $-NR^4R^5$  or  $-C(=O)NR^4R^5$ ;

$R^4$  is  $(C_1-C_6)$ alkyl substituted with  $-S(=O)CH_3$ ,  $-NHC(=O)CH_3$  or  $-C(=O)NR^7R^8$ ;

$R^5$  is H or methyl; and

$R^7$  and  $R^8$  are the same or different and are H or methyl.

Claim 4 (Cancelled)

Claim 5 (Presently Amended) A compound of claim 18 wherein:

$R^2$  is  $(C_1-C_6)$ alkyl substituted with  $-S(=O)R^3$ ;

$R^3$  is  $(C_1-C_6)$ alkyl optionally substituted with one to three groups selected from  $-S(=O)R^6$ ,  $-SO_2R^6$ ,  $-NR^7R^8$ ,  $-OR^7$ ,  $-NRC(=O)R^7$ ,  $-NR^iSO_2R^7$ ,  **$-NR^iSO_2R^6$** ,  $-C(=O)NR^7R^8$ ; and  $-O-C(=O)NR^7R^8$ ; and **wherein**

**$R^6$  is  $(C_1-C_6)$ alkyl and**  $R^7$  and  $R^8$  are the same or different and are H or  $(C_1-C_6)$ alkyl.

Claim 6 (Previously Presented) A compound of claim 18 wherein  $R^2$  is  $(C_1-C_6)$ alkyl substituted with  $-S(=O)R^3$ ; and  $R^3$  is  $(C_1-C_6)$ alkyl.

Claim 7 (Cancelled)

Claim 8 (Previously Presented) A compound of claim 18 wherein:

$R^2$  is  $Q^1-Q^2-Q^3-Q^4$ ;

$Q^1$  is a single bond;

$Q^2$  is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;

$Q^3$  is  $-CH_2-$ ;

$Q^4$  is a 5-membered aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl;

the atom of  $Q^2$  bound to  $Q^1$  is a carbon atom; and

the atom of  $Q^4$  bound to  $Q^3$  is a carbon atom.

Claim 9 (Previously Presented) A compound of claim 18 wherein  $R^1$  is  $-Cl$  or  $-F$ .

Claim 10 (Previously Presented) A compound of claim 18 wherein m is 2.

Claim 11 (Previously Presented) A compound according to claim 18 and selected from the group consisting of:

5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-chloro-5'-[(methylsulfinyl)methoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

5'-(2-[[2-(acetylamino)ethyl]amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-[(methylsulfinyl)methoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;  
and

8'-fluoro-5'-(2-[[1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl]oxy])-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one.


Claim 12 (Cancelled)

Claim 13 (Previously Presented) A method of treating acquired immune deficiency syndrome (AIDS) in a mammal, comprising administering to said mammal in need thereof a compound of claim 18.

Claims 14 to 16 (Cancelled)

Claim 17 (Previously Presented) A pharmaceutical composition comprising a compound of claim 18 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.

Claim 18 (Previously Presented) A compound of formula (I):



wherein

m is 1, 2 or 3;

R<sup>1</sup> is selected from CH<sub>3</sub>, Cl, Br and F;

R<sup>2</sup> is selected from

(a) Q<sup>1</sup>-Q<sup>2</sup>-Q<sup>3</sup>-Q<sup>4</sup> wherein:

Q<sup>1</sup> is a single bond or a linear or branched (C<sub>1</sub>-C<sub>4</sub>)alkylene group;

Q<sup>2</sup> is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;

Q<sup>3</sup> is a linear (C<sub>1</sub>-C<sub>4</sub>)alkylene group;

Q<sup>4</sup> is a 5 or 6-membered, aromatic heterocycle comprising 1 to 4 nitrogen atoms, said heterocycle being optionally substituted with methyl;

the atom of Q<sup>2</sup> bound to Q<sup>1</sup> is a carbon atom; and

the atom of Q<sup>4</sup> bound to Q<sup>3</sup> is a carbon atom;

(b) (C<sub>1</sub>-C<sub>6</sub>)alkyl, said alkyl group being substituted with a group selected from OR<sup>4</sup>, COOR<sup>4</sup>, NR<sup>4</sup>R<sup>5</sup>, NRC(=O)R<sup>4</sup>, C(=O)NR<sup>4</sup>R<sup>5</sup> and SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, wherein;

R is H or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>4</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl substituted with 1 to 3 groups selected from S(=O)R<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, NR<sup>6</sup>C(=O)R<sup>7</sup>, NR<sup>6</sup>SO<sub>2</sub>R<sup>6</sup>, C(=O)NR<sup>7</sup>R<sup>8</sup>, O-C(=O)NR<sup>7</sup>R<sup>8</sup> and SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, wherein R<sup>6</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl and R<sup>7</sup>, R<sup>7</sup> and R<sup>8</sup> are the same or different and are selected from H and (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

R<sup>5</sup> is selected from R<sup>4</sup>, H and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

(c) (C<sub>1</sub>-C<sub>6</sub>)alkyl, said alkyl group being:

substituted with 1 to 3 groups selected from  $\text{OC}(=\text{O})\text{R}^{4a}$ ,  $\text{SR}^{4a}$ ,  $\text{S}(=\text{O})\text{R}^3$ ,  $\text{NR}^a\text{COOR}^{4a}$ ,  $\text{NR}^a\text{-C}(=\text{O})\text{-NR}^{4a}\text{R}^{5a}$ ,  $\text{NR}^a\text{-SO}_2\text{-NR}^{4a}\text{R}^{5a}$ , and  $\text{NR}^a\text{-SO}_2\text{-R}^3$ , and

optionally substituted with OH or  $\text{OCH}_3$ ;

wherein

$\text{R}^a$  is selected from H and  $\text{CH}_3$ ;

$\text{R}^3$  is  $(\text{C}_1\text{-C}_6)$ alkyl, unsubstituted or substituted with 1 to 3 groups, selected from F, CN,  $\text{S}(=\text{O})\text{R}^6$ ,  $\text{SO}_3\text{H}$ ,  $\text{SO}_2\text{R}^6$ ,  $\text{C}(=\text{O})\text{-NH-SO}_2\text{-CH}_3$ ,  $\text{OR}^7$ ,  $\text{SR}^7$ ,  $\text{COOR}^7$ ,  $\text{C}(=\text{O})\text{R}^7$ ,  $\text{O-C}(=\text{O})\text{NR}^7\text{R}^8$ ,  $\text{NR}^7\text{R}^8$ ,  $\text{NR}^7\text{C}(=\text{O})\text{R}^7$ ,  $\text{NR}^7\text{SO}_2\text{R}^6$ ,  $\text{C}(=\text{O})\text{NR}^7\text{R}^8$  and  $\text{SO}_2\text{NR}^7\text{R}^8$ , wherein  $\text{R}^6$  is  $(\text{C}_1\text{-C}_6)$ alkyl and  $\text{R}^7$ ,  $\text{R}^8$  and  $\text{R}^6$  are the same or different and are selected from H and  $(\text{C}_1\text{-C}_6)$ alkyl;

$\text{R}^{4a}$  and  $\text{R}^{5a}$  are the same or different and are selected from H and  $\text{R}^3$ ;

their racemic forms, their isomers or their pharmaceutically acceptable salts.